Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Targeted pill trial offers hope for tough cancers with genetic flaw

NCT ID NCT06385483

Summary

This study is testing whether a pill called afatinib can help control advanced cancers that have a specific genetic change (EGFR mutation) and have stopped responding to standard treatments. It is for adults with various solid tumors or lymphomas (but not lung cancer or certain brain tumors). The goal is to see if blocking the faulty genetic signal can slow or shrink the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • ECOG-ACRIN Cancer Research Group

    Philadelphia, Pennsylvania, 19103, United States

Conditions

Explore the condition pages connected to this study.